Summary

Lung Cancer Diagnostics Market Trends & Summary

The global lung cancer diagnostics market is expected to grow significantly with an estimate of reaching US$ 38.00 billion by 2033 from US$ 20.28 billion in 2024. This growth has been due to a compound annual growth rate of 7.23% from 2025 to 2033. Growth has been spurred by the increased prevalence of lung cancer and awareness about early detection along with improved diagnostic technologies. Innovations in imaging, biomarkers, and non-invasive methods are among the reasons for the market's expansion.

The report Lung Cancer Diagnostics Market & Forecast covers by Diagnosis Test Type (Imaging Test, Biopsy, Sputum Cytology, Molecular Test, Others), Cancer Type (Non- Small Cell Lung Cancer, Small Cell Lung Cancer), End-User (Hospital Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes), Countries and Company Analysis 2025-2033.


Lung Cancer Diagnostics Industry Overview

Lung Cancer Diagnostics is the methods and technologies used to detect, identify, and evaluate lung cancer in patients. These diagnostics are important in determining the presence of cancerous cells, the type of lung cancer (small-cell or non-small-cell), and the stage of its progression. Early and accurate diagnosis is essential for improving patient outcomes, as it guides treatment decisions and helps monitor disease progression.

Diagnosing lung cancer is done with the use of different diagnostic tools, including chest X-rays, CT scans, and PET scans. All these helps to image the abnormality in the lungs. Biopsy-proven methods include bronchoscopy and needle aspiration. Other methods used are advanced molecular testing and biomarkers for the identification of genetic mutations, thereby guiding the application of the most appropriate personalized therapy. These diagnostics are essential to diagnose in the early stages, for planning treatment and monitoring therapy effectivity; thus, increasing the survival rate of the lung cancer patient along with improving their quality of life.


Growth Drivers for Lung Cancer Diagnostics Market

Advancement in Diagnostic Technologies

Developing cutting-edge diagnostics such as liquid biopsies, next-generation sequencing (NGS), and AI-driven imaging systems propels the market forward. Such new technologies improve on accuracy and allow non-invasive tests that also improve on early detection of lung cancer. For instance, liquid biopsies test circulating tumor DNA, giving crucial information regarding genetic mutations and treatment plans. AI algorithms improve imaging techniques, allowing for more accurate detection of tumors. Such technological advancements are bringing about more efficient diagnosis, reduced risks, and more personalized treatment plans, hence becoming an essential part of the growing market.


Growth in Lung Cancer Prevalence

The incidence of lung cancer is increasing globally and is one of the most significant growth factors. Higher incidence rates are attributed to factors such as smoking, pollution, occupational hazards, and aging populations. Lung cancer is still the leading cause of cancer-related deaths, according to global health organizations, and hence, requires strong diagnostic systems. The increasing patient population demands better diagnostic tools for early detection and better treatment outcomes. This trend will motivate health care providers and governments to invest in high-tech diagnostic infrastructure and public awareness campaigns, which will boost the market. As forecasted in February 2024, lung cancer was ranked the highest in cancer prevalence worldwide and affected 2.5 million people, which is likely to represent 12% of the total new cases.


Growing Interest in Early Detection and Screening Programs

Governments and health organizations are focusing on early detection through mass-screening programs. Programs like low-dose CT scanning target high-risk populations such as heavy smokers and individuals with a history of lung disease. Early detection of cancer has significantly improved the survival rate by detecting cancer at treatable stages. These programs are supported by public and private funding, encouraging research and development in diagnostic solutions. Increased awareness and availability of screening technologies promote adoption, in turn stimulating further growth of the market. This aggressive strategy resonates with worldwide initiatives aimed at reducing mortality rates due to lung cancer, positioning diagnostics as a key part of healthcare delivery systems. As of March 2023, End Lung Cancer Now (ELCN), an initiative of IU Simon Comprehensive Cancer Center, established the Lung Cancer Screening Taskforce, which is multidisciplinary. This aimed to come up with a blueprint on how the LCSP is transformed, scaled, and centralized by forming the task force.


Difficulties in the Lung Cancer Diagnostics Market

Expensive Diagnostic Techniques

The high cost of the advanced diagnostic tools in lung cancer includes molecular testing, liquid biopsies, and imaging technologies. These procedures often require specialized equipment, highly trained personnel, and sophisticated laboratory infrastructure, making them expensive for healthcare providers and patients. The financial burden in low- and middle-income countries limits access to these diagnostic services. Even in developed nations, affordability can hinder widespread adoption. High costs also affect reimbursement rates, creating barriers for providers and patients, ultimately slowing market penetration and hindering the widespread implementation of cutting-edge diagnostic solutions.


Limited Access in Developing Regions

Inadequate healthcare infrastructure and limited access to advanced diagnostics in developing regions continue to be a challenge. Many low- and middle-income countries lack the resources, trained professionals, and facilities to implement modern lung cancer diagnostic tools. In addition, geographic disparities in healthcare services contribute to unequal access, with rural and remote areas being the most underserved. Moreover, low awareness of lung cancer symptoms and diagnostic options contributes to late-stage diagnoses in these regions. This calls for significant investments in infrastructure, training programs, and public awareness campaigns to ensure equitable access and improved outcomes worldwide.


Lung Cancer Biopsy Diagnostics Market

The lung cancer biopsy diagnostics market is a critical segment of cancer diagnostics, focusing on extracting and analyzing lung tissue samples to detect malignancies. Common techniques include needle biopsy, bronchoscopy, and surgical biopsies, which provide useful information regarding the type of cancer and stage. Innovation in minimally invasive methodologies such as liquid biopsies, which analyze circulating tumor DNA for non-invasive detection, drives the market. Growth is fueled by rising lung cancer cases and the demand for early diagnosis and personalized treatment approaches. However, procedure-related risks, high costs, and limited accessibility in developing regions are barriers to the wider adoption of the market.


Non-small cell lung cancer diagnostics Market

The non-small cell lung cancer (NSCLC) diagnostics market deals with the diagnosis and assessment of the most common type of lung cancer, which comprises about 85% of cases. It encompasses imaging technologies, such as CT and PET scans, biopsy procedures, and molecular testing for mutations like EGFR, ALK, and KRAS. Precision medicine and targeted therapies increase demand for biomarker testing. Prevalence of NSCLC is growing with rising awareness for early diagnosis, and diagnostic techniques continue to evolve. Some drawbacks associated with this trend are cost and access limitations across various developing regions that deter it from reaching mainstream, resulting in the underuse of cancer care services.


Market for Lung Cancer Diagnostic Imaging Centers

The lung cancer diagnostic imaging centers offer services to diagnose and monitor lung cancer in its earliest stages. Key technologies utilized include chest X-rays, low-dose computed tomography, PET scans, and MRI for the visualizing the details of lung anomalies and staging tumors. Market growth is due to a rise in cases of lung cancer and increased emphasis on early detection through screening programs. Advances in technology through AI-enabled imaging and higher resolution devices increase the rate of diagnosis. However, the high costs of advanced imaging systems and limited access to these centers in rural and underserved areas are challenges. Investments in infrastructure and accessibility remain critical.


Canada Lung Cancer Diagnostics Market

The Canada lung cancer diagnostics market is growing steadily, driven by the rising cases of lung cancer and increasing awareness of early detection. Government policies supported the market through LDCT screening programs for targeted populations. The use of advanced diagnostic technologies, including biomarker testing, liquid biopsies, and AI-driven imaging technologies, increases the accuracy of diagnoses and the effectiveness of treatments for patients. More investment in new technologies and infrastructure must be made to bridge gaps and improve patient outcomes. In 2023, just over 31,000 Canadians are expected to be diagnosed with lung cancer, and it will kill more than 20,00 Canadians.


United Kingdom Lung Cancer Diagnostics Market

The United Kingdom's lung cancer diagnostics market is experiencing significant growth, fueled by increasing lung cancer prevalence and advancements in diagnostic technologies. Government-led programs like the NHS Targeted Lung Health Check Program encourage the early detection of lung disease in high-risk populations with low-dose CT. Advanced diagnostics, including liquid biopsies, molecular testing, and AI-powered imaging, improve diagnostic accuracy and facilitate personalized medicine. Despite this, regional disparities continue to exist in access to advanced diagnostics, and screening is delayed due to limitations in healthcare capacity. It is predicted that the average annual numbers of new cases of lung cancer in the UK could increase from around 55,400 cases in the years 2023-2025 to around 66,200 cases for 2038-2040.


India Lung Cancer Diagnostics Market

The lung cancer diagnostics market in India is growing due to growing numbers of prevalent lung cancers caused by increased tobacco smoking, air pollution, industrial exposure, and others. Demand for advanced diagnostic tools, such as imaging technologies (CT and PET scans), biopsies, and molecular testing, is increasing, particularly in urban areas. However, limited awareness, inadequate healthcare infrastructure in rural regions, and high costs of advanced diagnostics pose challenges. Government initiatives and public-private partnerships focus on improving early detection and access to affordable diagnostic solutions. India records about 75,000 new cases every year and a significant portion is detected at advanced stages.


UAE Lung Cancer Diagnostics Market

The UAE lung cancer diagnostics market is booming with the increased focus on early detection, increased incidence of cancer, and the improved diagnostic technologies. The rise in smoking, air pollution, and genetic factors also contribute to the increased number of lung cancer patients in the region. Advanced imaging technologies such as CT scans, PET scans, and biopsy procedures enhance the accuracy of diagnosis. Furthermore, the increasing trend towards personalized medicine and molecular testing is driving the market. The major challenges include high diagnostics cost and lack of access to healthcare facilities in remote areas. However, government initiatives and investments in healthcare enhance access to state-of-the-art diagnostic solutions.


Lung Cancer Diagnostics Market Segments

Diagnosis Test Type – Market breakup in 5 viewpoints:
1. Imaging Test
2. Biopsy
3. Sputum Cytology
4. Molecular Test
5. Others


Cancer Type – Market breakup in 2 viewpoints:
1. Non- Small Cell Lung Cancer
2. Small Cell Lung Cancer


End-User – Market breakup in 5 viewpoints:
1. Hospital Associated Labs
2. Independent Diagnostic Laboratories
3. Diagnostic Imaging Centers
4. Cancer Research Institutes
5. Others


Country – Market breakup in 25 Countries:
1. North America

1.1 United States
1.2 Canada

2. Europe

2.1 France
2.2 Germany
2.3 Italy
2.4 Spain
2.5 United Kingdom
2.6 Belgium
2.7 Netherlands
2.8 Turkey

3. Asia Pacific

3.1 China
3.2 Japan
3.3 India
3.4 South Korea
3.5 Thailand
3.6 Malaysia
3.7 Indonesia
3.8 Australia
3.9 New Zealand

4. Latin America

4.1 Brazil
4.2 Mexico
4.3 Argentina

5. Middle East & Africa

5.1 Saudi Arabia
5.2 UAE
5.3 South Africa


All the Key players have been covered from 3 Viewpoints:
• Overview
• Recent Development
• Revenue Analysis


Company Analysis:
1. llumina
2. Abbott Laboratories
3. Thermo Fisher Scientific, Inc.
4. QIAGEN N.V.
5. Roche Holding AG.
6. Sanofi S.A.
7. Agilent Technologies
8. bioMérieux.


Key Questions Answered in Report:
1. How big is the Lung Cancer Diagnostics industry?
The global Lung Cancer Diagnostics market size was valued at US$ 18.92 billion in 2023 and is expected to reach US$ 30.84 billion in 2030.

2. What is the Lung Cancer Diagnostics growth rate?
The global Lung Cancer Diagnostics market is expected to expand at a compound annual growth rate (CAGR) of 7.23% from 2024 to 2030.

3. Who are the key players in Lung Cancer Diagnostics industry?
Some key players operating in the Lung Cancer Diagnostics market includes llumina, Abbott Laboratories, Thermo Fisher Scientific, Inc, QIAGEN N.V., Roche Holding AG., Sanofi S.A., Agilent Technologies, and bioMérieux.

4. What are the factors driving the Lung Cancer Diagnostics industry?
Rising prevalence of lung cancer, improvements in diagnostic technologies such as liquid biopsies and CT scans, growing awareness of early detection, government screening programs, and the need for individualized treatment options are some of the factors propelling the lung cancer diagnostics market.

5. Which Region held the largest market share in the Lung Cancer Diagnostics industry?
North America is expected to hold the largest market share in the industry.

6. What segments are covered in the Lung Cancer Diagnostics Market report?
Diagnosis Test Type, Cancer Type, End-User, and Countries segment are covered in this report.

ページTOPに戻る

Table of Contents

1. Introduction


2. Research & Methodology


3. Executive Summary


4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges


5. Global Lung Cancer Diagnostics Market


6. Market Share
6.1 By Diagnosis Test Type
6.2 By Cancer Type
6.3 By EndUsers
6.4 By Country


7. Diagnosis Test Type
7.1 Imaging Test
7.2 Biopsy
7.3 Sputum Cytology
7.4 Molecular Test
7.5 Others


8. Cancer Type
8.1 Non- Small Cell Lung Cancer
8.2 Small Cell Lung Cancer


9. End-User
9.1 Hospital Associated Labs
9.2 Independent Diagnostic Laboratories
9.3 Diagnostic Imaging Centers
9.4 Cancer Research Institutes
9.5 Others


10. Country
10.1 North America

10.1.1 United States
10.1.2 Canada

10.2 Europe

10.2.1 France
10.2.2 Germany
10.2.3 Italy
10.2.4 Spain
10.2.5 United Kingdom
10.2.6 Belgium
10.2.7 Netherlands
10.2.8 Turkey

10.3 Asia Pacific

10.3.1 China
10.3.2 Japan
10.3.3 India
10.3.4 South Korea
10.3.5 Thailand
10.3.6 Malaysia
10.3.7 Indonesia
10.3.8 Australia
10.3.9 New Zealand

10.4 Latin America

10.4.1 Brazil
10.4.2 Mexico
10.4.3 Argentina

10.5 Middle East & Africa

10.5.1 Saudi Arabia
10.5.2 UAE
10.5.3 South Africa


11. Porter’s Five Analysis
11.1 Bargaining Power of Buyers
11.2 Bargaining Power of Suppliers
11.3 Degree of Rivalry
11.4 Threat of New Entrants
11.5 Threat of Substitutes


12. SWOT Analysis
12.1 Strength
12.2 Weakness
12.3 Opportunity
12.4 Threat


13. Company Analysis
13.1 llumina

13.1.1 Overviews
13.1.2 Recent Development
13.1.3 Revenues

13.2 Abbott Laboratories

13.2.1 Overviews
13.2.2 Recent Development
13.2.3 Revenues

13.3 Thermo Fisher Scientific, Inc

13.3.1 Overviews
13.3.2 Recent Development
13.3.3 Revenues

13.4 QIAGEN N.V.

13.4.1 Overviews
13.4.2 Recent Development
13.4.3 Revenues

13.5 Roche Holding AG.

13.5.1 Overviews
13.5.2 Recent Development
13.5.3 Revenues

13.6 Sanofi S.A.

13.6.1 Overview
13.6.2 Recent Development
13.6.3 Financial Insights

13.7 Agilent Technologies

13.7.1 Overview
13.7.2 Recent Development
13.7.3 Financial Insights

13.8 bioMérieux

13.8.1 Overview
13.8.2 Recent Development
13.8.3 Financial Insights